From: Managing an effective treatment for neuroleptic malignant syndrome
Effectiveness on the basis of increase of dosage | Relapse on the basis of decrease of dosage | Improvement of symptoms | ||||
---|---|---|---|---|---|---|
Fever | Rigor | Both | Not mentioned | |||
Dantrolene monotherapy | 2/37 (5.4%) | 3/37 (8.1%) | 9 (24.3%) | 4 (10.8%) | 9 (24.3%) | 15 (40.5%) |
Dantrolene with additive medication | 5/82 (6.1%) | 7/82 (8.5%) | 10 (12.2%) | 3 (3.7%) | 12 (14.6%) | 57 (69.5%) |
Other medication | 4/101 (4.0%) | 17/101 (16.8%) | 12 (11.9%) | 2 (2.0%) | 14 (13.9%) | 73 (72.3%) |
Only supportive therapy | Not applicable | Not applicable | 1 (2.0%) | - | 1 (2.0%) | 49 (96.1%) |